|
Title
|
|
|
|
Phase
|
|
|
|
Protocol IDs
|
|
|
|
Doxorubicin Hydrochloride Liposome or Capecitabine as First-Line Chemotherapy in Treating Women With Metastatic Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
SPRI-P04445
EU-20654, NCT00266799, SPRI-PELICAN
|
|
|
Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
|
|
|
|
Phase III, Phase II
|
|
|
|
D-0140
NCT00169104
|
|
|
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
|
|
|
Phase III, Phase II
|
|
|
|
20050113
NCT00243685
|
|
|
Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0226
CAN-NCIC-MAC7, S0226, NCT00075764
|
|
|
Letrozole With or Without Lapatinib in Treating Postmenopausal Women With Stage IV Breast Cancer
|
|
|
|
Phase III
|
|
|
|
GSK-EGF30008
UCLA-0311034-01, NCT00073528
|
|
|
Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer
|
|
|
|
Phase III
|
|
|
|
XRP9881B/3001
NCT00081796
|
|
|
A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer
|
|
|
|
Phase III
|
|
|
|
DOXIL-BCA-3001
NCT00091442
|
|
|
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine in Patients With Metastatic Breast or Colorectal Cancer
|
|
|
|
Phase III
|
|
|
|
MDA-CCC-0326
MDA-2005-0328, NCT00305643
|
|
|
ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
|
|
|
|
Phase III
|
|
|
|
EGF104383
NCT00272987
|
|
|
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)
|
|
|
|
Phase III
|
|
|
|
AVF3693g
NCT00281697
|
|